# US 2025/0375517 A1 · Peanut formulations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375517 A1
- Document ID: US20250375517A1
- Status: Published application
- Kind: A1
- Application number: 18/736,943
- Filed: 2024-06-07
- Published: 2025-12-11
- Earliest claimed: 2013-03-14
- Assignees: Societe des Produits Nestle S.A.
- Applicants: SociéTé Des Produits Nestlé S.A.
- Inventors: Bryan WALSER; Howard V. RAFF
- Web page: https://patentgrep.com/patent/US20250375517A1

## CPC

- A61K 39/35: Allergens
- A23L 25/30: {Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products (A23L25/10 and A23L25/40 take precedence)}
- A23L 33/185: Vegetable proteins
- A61K 9/4816: {Wall or shell material}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- G01N 33/483: Physical analysis of biological material
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/577: {tolerising response}
- G01N 2500/20: cell-free systems
- G01N 2800/24: Immunology or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.

## Claims

### Claim at position 1

1-55. (canceled)

### Claim 56

A composition comprising:
(a) defatted peanut flour comprising peanut protein in an amount of:
(i) 0.45 mg to 0.5 mg;
(ii) 0.9 mg to 1.1 mg;
(iii) 9 mg to 11 mg; or
(iv) 18 mg to 22 mg;
wherein the peanut protein comprises proteins Ara h1, Ara h2, and Ara h6;
(b) microcrystalline cellulose in an amount of from 60% to 90% w/w of the composition;
(c) pregelatinized starch in an amount of from 5% to 20% w/w of the composition;
(d) colloidal anhydrous silica in an amount of from 0.01% to 1% w/w of the composition; and
(e) magnesium stearate in an amount of from 0.01% to 1% w/w of the composition,
wherein the composition is encapsulated in a hydroxypropyl methylcellulose (HPMC) capsule that is configured to be opened.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the composition comprises 0.5 mg peanut protein.

### Claim 58 (depends on 56)

The composition of claim 56, wherein the composition comprises 1.0 mg peanut protein.

### Claim 59 (depends on 56)

The composition of claim 56, wherein the composition comprises 10 mg peanut protein.

### Claim 60 (depends on 56)

The composition of claim 56, wherein the composition comprises 20 mg peanut protein.

### Claim 61

A composition comprising:
(a) defatted peanut flour comprising peanut protein in an amount of 90 mg to 110 mg, wherein the peanut protein comprises proteins Ara h1, Ara h2, and Ara h6;
(b) microcrystalline cellulose in an amount of from 60% to 90% w/w of the composition;
(c) colloidal anhydrous silica in an amount of from 0.01% to 1% w/w of the composition; and
(d) magnesium stearate in an amount of from 0.01% to 1% w/w of the composition,
wherein the composition is encapsulated in a hydroxypropyl methylcellulose (HPMC) capsule that is configured to be opened.

### Claim 62 (depends on 61)

The composition of claim 61, wherein the composition comprises 100 mg peanut protein.

### Claim 63

A composition comprising:
(a) defatted peanut flour comprising peanut protein in an amount of 270 mg to 330 mg, wherein the peanut protein comprises proteins Ara h1, Ara h2, and Ara h6;
(b) microcrystalline cellulose in an amount of from 60% to 90% w/w of the composition;
(c) colloidal anhydrous silica in an amount of from 0.01% to 1% w/w of the composition; and
(d) magnesium stearate in an amount of from 0.01% to 1% w/w of the composition,
wherein the composition is a dispensable powder.

### Claim 64 (depends on 63)

The composition of claim 63, wherein the composition comprises 300 mg peanut protein.

### Claim 65 (depends on 56, 61, 63)

A method for treating peanut allergy in a subject by oral immunotherapy, the method comprising:
(i) administering to the subject an initial escalation of doses of the composition of claim 56 on a first day, wherein the initial escalation of doses comprises a plurality of doses administered in a single day in 30 minute intervals having a total peanut protein content of 0.5 mg, 1.0 mg, 1.5 mg, 3.0 mg, and 6.0 mg;
(ii) administering, if the subject tolerates the initial escalating dose, an up-dosing phase of oral immunotherapy, the up-dosing phase comprising a plurality of doses of the composition of claim 56 and/or claim 61, wherein the plurality of doses comprises a total daily peanut protein content of 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg, 240 mg, and 300 mg, and wherein each dose is administered daily over a period of at least two weeks before the next dose is administered; and
(iii) administering, if the subject tolerates the up-dosing phase, a daily maintenance phase dose of the composition of claim 63, wherein each daily maintenance phase dose comprises 300 mg peanut protein.

### Claim 66 (depends on 65)

The method of claim 65, further comprising mixing one or more doses with food prior to the administration.

### Claim 67 (depends on 65)

The method of claim 65, wherein the 3 mg dose of the up-dosing phase comprises three 1 mg doses.

### Claim 68 (depends on 65)

The method of claim 65, wherein the 6 mg dose of the up-dosing phase comprises six 1 mg doses.

### Claim 69 (depends on 65)

The method of claim 65, wherein the 12 mg dose of the up-dosing phase comprises two 1 mg doses and one 10 mg dose.

### Claim 70 (depends on 65)

The method of claim 65, wherein the 20 mg dose of the up-dosing phase comprises one 20 mg dose.

### Claim 71 (depends on 65)

The method of claim 65, wherein the 40 mg dose of the up-dosing phase comprises two 20 mg doses.

### Claim 72 (depends on 65)

The method of claim 65, wherein the 80 mg dose of the up-dosing phase comprises four 20 mg doses.

### Claim 73 (depends on 65)

The method of claim 65, wherein the 120 mg dose of the up-dosing phase comprises one 20 mg dose and one 100 mg dose.

### Claim 74 (depends on 65)

The method of claim 65, wherein the 160 mg dose of the up-dosing phase comprises three 20 mg doses and one 100 mg dose.

### Claim 75 (depends on 65)

The method of claim 65, wherein the 200 mg dose of the up-dosing phase comprises two 100 mg doses.

### Claim 76 (depends on 65)

The method of claim 65, wherein the 240 mg dose of the up-dosing phase comprises two 20 mg doses and two 100 mg doses.

### Claim 77 (depends on 65)

The method of claim 65, wherein the 300 mg dose of the up-dosing phase comprises one 300 mg dose.
